A Phase II Trial of DaunoXome, Liposome- Encapsulated Daunorubicin, in Patients with Metastatic Adenocarcinoma of the Colon

Context: Liposomal encapsulation of drugs can potentially ameliorate toxicities and improve acute and chronic tolerance. The increased uptake of liposomes by colon adenocar-cinoma cell lines may enable DaunoXome to circumvent the p-glycoprotein-mediated anthracycline resistance of colon cancer cells